Relapsed/ Refractory T-cell Malignancies
1 clinical trials · Condition
◉ Watch Relapsed/ Refractory T-cell Malignancies
| Record | Firm | Date |
|---|---|---|
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (NCT04447027) | National Cancer Institute (NCI) | 2020-12-17 |
Track Relapsed/ Refractory T-cell Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.